HCA Projects 2026 Adjusted EBITDA of $15.4B-$16.1B, Adding Key Profitability Metric
HCA is trading near its 52-week low of $330 (12% above the low).
Summary
HCA Healthcare issued full-year 2026 adjusted EBITDA guidance of $15.4 billion to $16.1 billion, a new profitability metric not previously disclosed. This follows the July 14 preliminary Q2 revenue beat and EPS guidance cut, which cited rising uncompensated care. The EBITDA range provides a clearer view of operating leverage and cash generation potential, helping traders assess margin resilience amid cost pressures. With a $83.5 billion market cap, the guidance frames valuation and debt-service capacity. The next catalyst is the full Q2 earnings release, where management commentary on cost trends and the $10 billion buyback program will be critical.
At the time of this announcement, HCA was trading at $369.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $83.5B. The 52-week trading range was $330.00 to $556.52. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.